Hepatology Forum最新文献

{"title":"Non-invasive tests fail to ensure therapeutic precision for resmetirom in MASLD.","authors":"Gupse Adali, Remzi Adnan Akdogan","doi":"10.14744/hf.2025.2025.0055","DOIUrl":"10.14744/hf.2025.2025.0055","url":null,"abstract":"","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":"6 3","pages":"89-90"},"PeriodicalIF":2.1,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12268762/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144675970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of orlistat for the treatment of metabolic dysfunction-associated steatotic liver disease patients: A systematic review and meta-analysis.","authors":"Ariyan Ayati, Iman Elahi Vahed, Yasaman Rahimi, Shima Karbasi, Ali Safdari, Mahkameh Razaghi, Aida Bazrgar, Melika Arab Bafrani, Mohammad Mehdi Mousavi Nasab, Masoud Noroozi, Shokoofeh Noori, Mohammad Rahmanian","doi":"10.14744/hf.2024.2024.0047","DOIUrl":"10.14744/hf.2024.2024.0047","url":null,"abstract":"<p><p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is a persistent hepatic condition linked with cardiovascular disorders and metabolic disturbances. Characterized by inflammation, fat accumulation, and fibrosis within the liver, MASLD can develop into liver cancer and cirrhosis. With a global prevalence of 32.4%, the condition parallels rising obesity rates. Orlistat inhibits lipase enzymes and, therefore, reduces dietary fat absorption, which may benefit MASLD patients. The present systematic review and meta-analysis were performed in accordance with PRISMA guidelines. Searches of PubMed, Scopus, Web of Science, and Embase up to January 2025 were performed using specific keywords and MeSH terms. Bias assessment and data extraction were conducted using Joanna Briggs Institute (JBI) tools independently by two researchers. Statistical analyses were performed with Stata version 14, calculating standardized mean differences, 95% confidence intervals (CI), and heterogeneity (by performing Cochran's Q test and I² index). Moreover, meta-regression, subgroup analyses, and sensitivity analyses were conducted. Eleven studies featuring 582 participants were included. Orlistat treatment induced a significant reduction in levels of alanine transaminase (ALT) (SMD = -26.23; 95% CI = -34.70 to -17.76) and aspartate aminotransferase (AST) (SMD = -19.62; 95% CI = -28.33 to -10.92). Furthermore, reductions in HOMA-IR, body mass index, cholesterol, insulin, and waist circumference were observed. The included studies exhibited low to moderate heterogeneity for most outcomes, indicating consistent results across trials. Orlistat significantly improved AST, ALT, and some other metabolic parameters in MASLD patients, suggesting its potential as an additional treatment option. However, the outcome must be interpreted cautiously, considering study heterogeneity. Further high-quality, multicenter research is necessary to confirm these results.</p>","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":"6 3","pages":"129-136"},"PeriodicalIF":1.2,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12268761/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144675968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Isolated IgG4-related sclerosing cholangitis mimicking hilar cholangiocarcinoma: A case report and review.","authors":"Gokalp Okut, Mehmet Alperen Ugur, Halil Yildiz, Birsen Gizem Ozamrak, Sait Murat Dogan","doi":"10.14744/hf.2025.2025.0003","DOIUrl":"10.14744/hf.2025.2025.0003","url":null,"abstract":"<p><p>Immunoglobulin G4-related sclerosing cholangitis (IgG4-SC) is a rare autoimmune disease characterized by fibroinflammatory lesions and bile duct strictures, often associated with type 1 autoimmune pancreatitis (AIP). Isolated IgG4-SC, occurring without AIP, is particularly uncommon and can clinically and radiologically mimic hilar cholangiocarcinoma, presenting with jaundice and bile duct strictures. Accurate differentiation between these conditions is essential, as surgical resection is the standard treatment for cholangiocarcinoma, whereas steroid therapy is the first-line treatment for IgG4-SC. This case report discusses a 55-year-old female patient who underwent left hepatectomy due to a hilar bile duct stricture initially suspected to be cholangiocarcinoma but was ultimately diagnosed as isolated IgG4-SC based on postoperative histopathological and immunohistochemical findings. The report highlights the diagnostic challenges of isolated IgG4-SC and emphasizes the importance of integrating histology, imaging, and serology to prevent unnecessary surgical interventions.</p>","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":"6 4","pages":"166-169"},"PeriodicalIF":2.1,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12536417/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145348829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of long-term potent antiviral therapy on the natural course of disease in patients with hepatitis B virus-related cirrhosis.","authors":"Guner Kilic, Tugce Guvenir, Emin Bodakci, Zeynep Melekoglu Ellik, Hale Gokcan, Ramazan Idilman","doi":"10.14744/hf.2024.2024.0069","DOIUrl":"10.14744/hf.2024.2024.0069","url":null,"abstract":"<p><strong>Background and aim: </strong>The present study compared the long-term efficacy of weak and potent antiviral treatments in patients with hepatitis B virus (HBV)-related cirrhosis.</p><p><strong>Materials and methods: </strong>A total of 120 patients with HBV-related cirrhosis were enrolled. The primary outcome measure was viral suppression. A secondary outcome measure was to determine the development of decompensation or hepatocellular carcinoma (HCC).</p><p><strong>Results: </strong>The virological response (VR) was significantly better in patients treated with potent antiviral agents than in those treated with weaker antiviral agents over time (p<0.001). With intention-to-treat, the VR after 1 year, 2 years, 3 years, and 4 years of potent antiviral treatment was 69.7%, 77.0%, 82.2%, and 81.2%, respectively, while the VR with weak antiviral therapies was 50.0%, 41.6%, 37.5%, and 37.5%. HBeAg (Hepatitis B e-Antigen) loss was achieved in 30.4% of HBeAg-positive patients. None of the patients had experienced HBsAg loss while on antiviral treatment. New HCC developed in 10 patients. The cumulative probability of the development of HCC was 2.6% at 1 year, 6.8% at 2 years, and 8.7% at 3 and 5 years of antiviral therapy. MELD scores among patients treated with potent antiviral treatment significantly improved from baseline to week 60 (p=0.006). Antiviral therapies were well tolerated.</p><p><strong>Conclusion: </strong>Potent antiviral treatment effectively maintained VR in the long-term follow-up of patients with HBV-related cirrhosis. HCC may still develop, albeit at a lower rate in these patients.</p>","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":"6 4","pages":"141-145"},"PeriodicalIF":2.1,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12536419/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145348810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effects of hepatocyte-specific MafF overexpression on FFA or ETOH induced hepatocyte steatosis and its underlying mechanism.","authors":"Jinhui Cai, Shen Wang, Yanmin Feng, Lin Zheng, Qiuting Liang, Yanqing Liang, Xiaoxia Ye","doi":"10.14744/hf.2024.2024.0030","DOIUrl":"10.14744/hf.2024.2024.0030","url":null,"abstract":"<p><strong>Background and aim: </strong>The transcription factor MafF is a novel regulator of adipogenesis, but its role in hepatic steatosis remains unclear. This study aimed to explore the impact of MafF on hepatocyte steatosis and its underlying mechanisms.</p><p><strong>Materials and methods: </strong>A stable MafF-overexpressing cell line was established using lentiviral infection. RT-qPCR and Western blot analysis confirmed MafF expression. Free fatty acid (FFA) or ethanol (ETOH) induction was used to simulate hepatocyte steatosis in non-alcoholic or alcoholic fatty liver disease (NAFLD or AFLD). Cell activity and lipid accumulation were assessed through the CCK-8 assay, Calcein-AM/PI staining, and Oil Red O staining. The changes in lipid metabolism-related gene expression before and after FFA or ETOH treatment were detected using RT-qPCR.</p><p><strong>Results: </strong>FFA or ETOH induced lipid accumulation in hepatocytes, and overexpression of MafF significantly ameliorated ETOH-induced hepatocyte steatosis but had little effect on FFA-induced hepatocyte steatosis. MafF overexpression significantly reduced the expression of peroxisome proliferator-activated receptor gamma (PPARG), acetyl-CoA carboxylase (ACC), and lipoprotein lipase (LPL) in hepatocytes. Upon FFA induction, control (NC) cells exhibited downregulation of these genes, whereas MafF-overexpressing cells upregulated LPL expression. In contrast, under ETOH treatment, NC cells upregulated these genes, while MafF-overexpressing cells showed downregulation.</p><p><strong>Conclusion: </strong>This study highlighted the regulation of lipid-related genes by MafF, including PPARG, ACC, and LPL, and its effect on FFA- and ETOH-induced hepatocellular lipid accumulation in distinct ways. MafF showed a more pronounced improvement in ETOH-induced hepatocyte steatosis, providing crucial insights into MafF's role in hepatic lipid metabolism and potential therapeutic strategies for NAFLD and AFLD.</p>","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":"6 3","pages":"91-98"},"PeriodicalIF":1.2,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12268770/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144675975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Liver transplantation for alcohol-associated liver disease: The changing landscape.","authors":"Eda Yildiz, Duha Zaffar, N Begum Ozturk, Merve Gurakar, A Eylul Donmez, Merih Deniz Toruner, Cem Simsek, Ahmet Gurakar","doi":"10.14744/hf.2024.2024.0057","DOIUrl":"https://doi.org/10.14744/hf.2024.2024.0057","url":null,"abstract":"<p><p>Alcoholic liver disease(ALD) is considered as a growing public health issue with universally increasing disease burden. Various genetic and environmental factors play role in its etiology. ALD recently has become the major indication for Liver Transplantation (LT). Most LT programs select their candidates by adhering to six months of alcohol abstinence policy. Nevertheless, early liver transplantation (ELT) has become a subject of research, both in Europe and the United States, as an effective and lifesaving option among highly selected severe alcohol-associated hepatitis (SAH) patients. ELT is a promising way in the management of ALD, perhaps changing clinical practice for carefully selected patient groups.</p>","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":"6 2","pages":"77-86"},"PeriodicalIF":1.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11999900/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144036972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Kaposi's sarcoma developing in a geriatric patient with autoimmune hepatitis shortly after immunsupressive treatment.","authors":"Dilara Turan Gokce, Derya Ari, Omer Ozturk, Meral Akdogan Kayhan","doi":"10.14744/hf.2024.2024.0042","DOIUrl":"https://doi.org/10.14744/hf.2024.2024.0042","url":null,"abstract":"","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":"6 2","pages":"87-88"},"PeriodicalIF":1.2,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11999901/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144052504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of dermatomyositis and autoimmune hepatitis: A case report.","authors":"Saïd Fatma, Naceur Ines, Jridi Maysam, Achour Tayssir Ben, Smiti Monia","doi":"10.14744/hf.2024.2024.0032","DOIUrl":"10.14744/hf.2024.2024.0032","url":null,"abstract":"<p><p>The association of dermatomyositis (DM) and autoimmune hepatitis (AIH) is rare and presents a diagnostic and therapeutic challenge. We describe the case of a 36-year-old man with DM diagnosed in 2012 and treated with corticosteroid and methotrexate. The patient achieved total remission 18 months later. In 2022, an AIH was diagnosed (cytolysis, cholestasis, anti-LC1, and anti-SLA antibodies) while DM was in remission. Liver function normalized after two months of treatment with mycophenolate mofetil and corticosteroids. Liver damage in systemic autoimmune diseases can result from viral, iatrogenic, or autoimmune processes. The association between DM and AIH is exceptional and has only been documented in one previous observation. Autoantibodies are essential for diagnosing and managing patients with inflammatory myopathy and AIH. In conclusion, this exceptional association of AIH and DM raises many questions regarding the presence of etiopathogenic links, such as genetic predisposition, autoimmunity disorders, viral infection triggers, or simply a happenstance.</p>","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":"6 3","pages":"116-117"},"PeriodicalIF":1.2,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12268768/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144675964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A rare clinic in hepatocellular cancer: Metastasis of the nasopharynx.","authors":"Fatih Emin Ozturk, Coskun Ozer Demirtas, Fuat Jafarov, Beyza Keskin Ozturk, Feyza Dilber","doi":"10.14744/hf.2024.2024.0023","DOIUrl":"https://doi.org/10.14744/hf.2024.2024.0023","url":null,"abstract":"<p><p>Hepatocellular cancer (HCC) is the most common primary malignant tumor of the liver. The organs that HCC most commonly metastasizes to are the lungs, intra-abdominal lymph nodes, bones, and adrenal glands. Brain metastases have been reported rarely. Herein, we report a 54-year-old female patient who was diagnosed with cryptogenic cirrhosis by liver biopsy in 2010. Solid lesions were detected on radiological examination during follow-up in 2019. The patient's complaints of severe headache, nausea, and vomiting continued during the follow-up, and imaging was performed. A contrast-enhancing lesion, 2 cm in size, was reported in the left half of the clivus on T1 examination after intravenous contrast administration. A biopsy was performed on the mass extending from the clivus to the nasopharynx. The biopsy concluded that it was an HCC metastasis. Intracranial metastases of HCC have been reported very rarely compared to other extrahepatic sites. HCC cases with intracranial metastases have a poor prognosis. Intracranial metastases should be considered in the differential diagnosis in patients presenting with central nervous system findings.</p>","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":"6 2","pages":"62-64"},"PeriodicalIF":1.2,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11999899/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144021543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dynamic changes in liver stiffness measurements using transient elastography in hemodialysis patients.","authors":"Nottawan Suksai, Somchai Yongsiri, Raweewan Witoon, Rachaneeporn Chueansuwan, Anothai Juttuporn","doi":"10.14744/hf.2024.2024.0044","DOIUrl":"https://doi.org/10.14744/hf.2024.2024.0044","url":null,"abstract":"<p><strong>Background and aim: </strong>The impact of fluid status changes on liver stiffness measurements (LSM) using transient elastography (TE) in dialysis patients remains unclear. This study aimed to evaluate LSM variations during hemodialysis (HD) and analyze contributing factors.</p><p><strong>Materials and methods: </strong>A cross-sectional study was conducted on dialysis patients at a tertiary care hospital. TE and bioelectrical impedance analysis were performed at four time points: before dialysis, immediately after, the first day after, and the second day after dialysis. LSM values were compared across these time points.</p><p><strong>Results: </strong>Seventy patients were enrolled, with two cases showing consistently extremely elevated LSM values exceeding 20 kPa, considered outliers. The mean LSM values were 7.6±7.0 kPa before dialysis, 6.12±2.94 kPa immediately after, 6.64±5.27 kPa on the first day, and 6.94±5.12 kPa on the second day after dialysis. The mean pre-HD LSM was significantly higher than immediately after and on the first day after dialysis, with mean differences of 1.54 kPa (95% CI 0.22-2.86, p=0.02) and 1.02 kPa (95% CI 0.15-1.9, p=0.02), respectively. The ultrafiltration volume positively correlated with the LSM difference pre- and post-HD (r=0.315, p=0.008). Patients with residual fluid overload had significantly higher post-HD LSM compared to euvolemic patients (p=0.003).</p><p><strong>Conclusion: </strong>LSM values significantly decreased after dialysis and remained lower for up to 24 hours. Transient elastography should preferably be performed within 24 hours post-dialysis when the patient is in a euvolemic state.</p>","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":"6 2","pages":"57-61"},"PeriodicalIF":1.2,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11999895/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144043387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}